Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy

Seres Therapeutics, Inc.

Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.
SER-155 Phase 1b biomarker: significant decrease in fecal albumin (epithelial barrier integrity) vs placebo.
FDA granted Breakthrough Therapy designation for SER-155 in allo-HSCT in Dec 2024.
Briefing Book submitted for next registrational study; FDA feedback expected Q1 2025.
SER-155 results accepted for oral presentation at TANDEM Meeting Feb 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.